Linked e-resources
Details
Table of Contents
Evolution of the development of PARP inhibitors
Exploiting cancer synthetic lethality in cancer Lessons learnt from PARP inhibitors
Mechanisms of PARP inhibitor resistance
Development of homologous recombination functional assays for targeting the DDR
Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer
Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer
Development of PARP inhibitors in targeting castration-resistant prostate cancer
Strategies for the management of patients with pancreatic cancer with PARP inhibitors
Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges
Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents
Combining PARP inhibition and immunotherapy in BRCA-associated cancers
Mitotic MTH1 inhibitors in treatment of cancer
Targeting ATR in cancer medicine
Targeting polymerase Theta (POLq) for cancer therapy
Targeting DNA-PK
WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI).
Exploiting cancer synthetic lethality in cancer Lessons learnt from PARP inhibitors
Mechanisms of PARP inhibitor resistance
Development of homologous recombination functional assays for targeting the DDR
Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer
Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer
Development of PARP inhibitors in targeting castration-resistant prostate cancer
Strategies for the management of patients with pancreatic cancer with PARP inhibitors
Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges
Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents
Combining PARP inhibition and immunotherapy in BRCA-associated cancers
Mitotic MTH1 inhibitors in treatment of cancer
Targeting ATR in cancer medicine
Targeting polymerase Theta (POLq) for cancer therapy
Targeting DNA-PK
WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI).